Journal of Clinical Endocrinology & Metabolism, Vol 75, 1104-1109, Copyright © 1992 by Endocrine Society

ARTICLES

Serum propeptide and intact molecular osteocalcin in normal children and children with growth hormone (GH) deficiency: a potential marker of bone growth and response to GH therapy

S Kanzaki, K Hosoda, T Moriwake, H Tanaka, T Kubo, M Inoue, J Higuchi, T Yamaji and Y Seino
Department of Pediatrics, Okayama University Medical School, Japan.

To establish a sensitive marker for bone formation we have developed a sandwich enzyme-linked immunosorbent assay for intact osteocalcin (OC) and its propeptide. Serum levels of these peptides were studied in 185 normal children, aged 4-15 yr, and in 23 GH-deficient children treated with GH. The serum levels of the propeptide in normal prepubescent children were 1.43 +/- 0.23 (mean +/- SE) micrograms/L in boys and 1.53 +/- 0.23 micrograms/L in girls. The peak value occurred at the age of 13 yr in boys (2.91 +/- 0.42 micrograms/L) and 11 yr in girls (2.34 +/- 0.34 micrograms/L). The serum intact OC levels in prepubescent boys and girls were 18.8 +/- 2.1 and 20.7 +/- 2.1 micrograms/L, respectively, and these levels increased to 41.0 +/- 3.7 micrograms/L in boys aged 13 yr and to 27.0 +/- 2.5 micrograms/L in girls aged 11 yr. In the GH- deficient patients, a 2.3-fold increase in the propeptide level and a 1.7-fold increase in the intact OC level was observed after 1 month of GH therapy. Serum propeptide and intact OC levels after 1 month of GH therapy correlated with the growth response after 12 months of GH therapy (r = 0.660 and P < 0.01, for propeptide; r = 0.537 and P < 0.01 for intact OC). These results show that since both propeptide and intact OC in serum were increased when the growth rate was elevated, these peptides are sensitive markers of bone formation. Serum levels of these peptides, particularly propeptide, after 1 month of GH therapy might be a helpful predictor of the growth response to long term GH therapy.

This article has been cited by other articles:

				C Land, W F Blum, A Stabrey, and E Schoenau Seasonality of growth response to GH therapy in prepubertal children with idiopathic growth hormone deficiency Eur. J. Endocrinol., May 1, 2005; 152(5): 727 - 733. [Abstract] [Full Text] [PDF]

				R. Eastell Role of oestrogen in the regulation of bone turnover at the menarche J. Endocrinol., May 1, 2005; 185(2): 223 - 234. [Abstract] [Full Text] [PDF]

				S. Wickman, E. Kajantie, and L. Dunkel Effects of Suppression of Estrogen Action by the P450 Aromatase Inhibitor Letrozole on Bone Mineral Density and Bone Turnover in Pubertal Boys J. Clin. Endocrinol. Metab., August 1, 2003; 88(8): 3785 - 3793. [Abstract] [Full Text] [PDF]

				R. S. Swerdloff, C. J. Bagatell, C. Wang, B. D. Anawalt, N. Berman, B. Steiner, and W. J. Bremner Suppression of Spermatogenesis in Man Induced by Nal-Glu Gonadotropin Releasing Hormone Antagonist and Testosterone Enanthate (TE) Is Maintained by TE Alone J. Clin. Endocrinol. Metab., October 1, 1998; 83(10): 3527 - 3533. [Abstract] [Full Text]

				A. M. Boot, M. A. M. J. Engels, G. J. M. Boerma, E. P. Krenning, and S. M. P. F. de Muinck Keizer-Schrama Changes in Bone Mineral Density, Body Composition, and Lipid Metabolism during Growth Hormone (GH) Treatment in Children with GH Deficiency J. Clin. Endocrinol. Metab., August 1, 1997; 82(8): 2423 - 2428. [Abstract] [Full Text] [PDF]

				H. Tobiume, S. Kanzaki, S. Hida, T. Ono, T. Moriwake, S. Yamauchi, H. Tanaka, and Y. Seino Serum Bone Alkaline Phosphatase Isoenzyme Levels in Normal Children and Children with Growth Hormone (GH) Deficiency: A Potential Marker for Bone Formation and Response to GH Therapy J. Clin. Endocrinol. Metab., July 1, 1997; 82(7): 2056 - 2061. [Abstract] [Full Text] [PDF]

				S. Mora, H S. Raffaele, G. Weber, A. Bellini, C. Bianchi, and G. Chiumello Bone Modeling Alteration in Premature Infants Arch Pediatr Adolesc Med, November 1, 1994; 148(11): 1215 - 1217. [Abstract] [PDF]